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ABSTRACT 
Poly(ADP-ribose) polymerase (PARP) is involved in the pathogenesis of cell dysfunction, inflammation and 
organ failure during septic shock. The goal of the current study was to investigate the efficacy and safety of the 
clinically approved PARP inhibitor olaparib in experimental models of oxidative stress in vitro and in sepsis in 
vivo. ln mice subjected to cecal ligation and puncture (CLP) organ injury markers, circula ting and splenic im-
mune cell distributions, circulating mediators, DNA integrity and survival was measured. ln U937 cells subjected 
to oxidative stress, cellular bioenergetics, viability and DNA integrity were measured. Olaparib was used to 
inhibit PARP. The results show that in adult male mice subjected to CLP, olaparib (1-10 mg/kg i.p.) improved 
multiorgan dysfonction. Olaparib treatrnent reduced the degree of bacterial CFUs. Olaparib attenuated the in-
creases in the levels of several circulating mediators in the plasma. ln the spleen, the number of CD4 + and 
CDS + lymphocytes were reduced in response to CLP; this reduction was inhibited by olaparib treatrnent. Treg 
but not Thl 7 lymphocytes increased in response to CLP; these cell populations were reduced in sepsis when the 
animais received olaparib. The Thl 7 /Treg ratio was lower in CLP-olaparib group than in the CLP control group. 
Analysis of miRNA expression identifi ed a multitude of changes in spleen and circulating white blood cell miRNA 
levels after CLP; olaparib treatrnent selectively modulated these responses. Olaparib extended the survival rate of 
mice subjected to CLP. ln contrast to males, in female mice olaparib did not have significant protective effects in 
CLP. ln aged mice olaparib exerted beneficial effects that were Jess pronounced than the effects obtained in 
young adult males. ln in vitro experiments in U937 cells subjected to oxidative stress, olaparib (1-100 µM) 
inhibited PARP activity, protected against the Joss of cell viability, preserved NAD + levels and improved cellular 
bioenergetics. ln none of the in vivo or in vitro experiments did we observe any adverse effects of olaparib on 
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nuclear or mitochondrial DNA integrity. In conclusion, olaparib improves organ function and extends survival in 
septic shock. Repurposing and eventual clinical introduction of this clinically approved PARP inhibitor may be 
warranted for the experimental therapy of septic shock. 
1. Introduction 
Sepsis is a life-threatening systemic inflammatory disease affecting 
several million people annually worldwide. It is associated with mor-
tality rates of 20-40%. lts ftequency increases every year, in excess of 
the growth and aging of our population. The outcomes of sepsis are 
markedly worse in the elderly [1,2]. On the other hand, the female 
gender (in the pre-menopausal stage) tends to provide some protection 
against sepsis-associated mortality [3,4]. Despite extensive research 
and despite a large number of pivotal clinical trials targeting various 
pathways in immune, inflammatory and coagulation abnormalities in 
sepsis/septic shock, no specific pharmacological or immunological 
therapies are approved for the treatment of this condition. 
More than two decades ago, the constitutive nuclear and mi-
tochondrial enzyme poly(ADP-ribose) polymerase (PARP) emerged as a 
potential therapeutic target for various forms of critical illness, in-
cluding sepsis. Several lines of studies, utilizing PARP inhibitors of 
various structural classes, as well as PARP-1-deficient mice indicated 
that PARP inhibition exerts beneficial effects on organ function, vas-
cular function, and survival [5-19]. For instance, PARP-1 knockout 
mice showed, after cecal ligation and puncture (CLP), lower plasma 
levels of1NF-a, IL-6 and IL-10 [8 ]. In an intraperitoneal bacterial sepsis 
model, pigs treated with PARP inhibitors showed better survival after 
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24 h and 96 h, decreased bacteremia, attenuated 1NFa plasma levels 
and protected against the cardiovascular dysfunction when compared 
to untreated animals [9]. Moreover, treatment with a PARP inhib itor 
exerted a protective effect against apoptosis in the hearts of rats sub-
jected to CLP [16]. 
Although PARP activation clearly plays a pathophysiological role in 
sepsis, clinical translation of this concept was not possible, because 
there were no clinically approved drugs to inhibit PARP. Recently, 
several classes of PARP inhibitors have been approved for clinical use, 
in the field of oncology. This developmen t is based on an independent 
line of research, one that demonstrated that in cancer cells, PARP in-
hibition can indu ce cell dea th and can potentia te the efficacy of var ious 
classes of anticancer agents [20,21]. One of the clinically approved 
PARP inhibitor drugs is olaparib (Lynparza), a competitive PARP in-
hibitor that inhibits the b inding of NAD+ (the substrate of PARP) into 
the catalytic site of PARP. 
As outlined in our recent position paper, the clinical approval of 
PARP inhibitors opens the door for potential repurposing of these drugs 
for various non-oncological indications, with sepsis/ septic shock being 
one of the prime candidates for such repurposing efforts [19 ]. However, 
additional preclinical work is needed to lay the groundwork for such 
repurposing efforts. As described in detail [19 ], such work needs to 
focus both on efficacy endpoints, as w ell as safety endpoints - chiefly, 
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Fig. 1. Effect of olaparib on Jung, liver and spleen MPO and MDA levels in young male Balb/ c mice subjected to CLP. (A): Lung, liver and spleen MPO levels 
(expressed as milliunits [mU]!gram tissue) and (B): Jung, liver and spleen MDA levels (expressed as µM/gram tissue) are shown in sham mi ce (not subjected to CLP) 
("Sham"), in vehicle-treated mice subjected to CLP for 24 h ("CLP'1 and in mice subjected to CLP in the presence ofvarious doses of olaparib ("CLP Olaparib 1 mg/ kg", 
CLP Olaparib 3 mg/kg" and "CLP Olaparib 10 mg/kg'1. Data are shown as mean ± SEM of 10 animais for each group; *p < 0.05 shows significant inc rease in MPO 
in response to CLP, compared to the sham group; # p < 0.05 shows significant protective effec t of olaparib in CLP mice compared to vehicle-treated CLP mice. 
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on DNA integrity, considering the fact that PARP has been long con-
sidered an enzyme that has an important raie in the facilitation of DNA 
repair. The current report describes the results of such a project. Our 
experiments incorporated a standard mode! of sepsis (induced by cecal 
ligation and puncture) and evaluated multiple efficacy endpoints (pri-
marily focusing on multiorgan injury), as well as safety endpoints 
(mitochondrial and nuclear DNA integrity). We have also conducted an 
in vitro sub-study (human monocytic cells subjected to oxidative stress) 
- once again, bath focusing on efficacy endpoints (cell viability, cellular 
bioenergetics) as well as safety endpoints (DNA integrity). The results 
of the current study demonstrate the efficacy of olaparib on multiple 
outcome variables, and do not identify any significant adverse effects of 
ALP 
;:::1 i 0 0 6 200 150 .... - 100 :::> 50 * 
ALT 
the PARP inhibitor on DNA integrity. Thus, the data presented in the 
current report !end support for repurposing and clinical introduction of 
the PARP inhibitor olaparib for the experimental therapy of septic 
shock. 
2. Materials and methods 
2.1. Animais 
Male or female C57BL6 mice (8-72 weeks old) were obtained from 
Jackson Laboratories. Animais were kept in a 12 h - 12 h light / dark 
cycle at 21-23 'C with free access to standard chow diet. 
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Fig. 2. Effect of olaparib on selected parameters of organ injury in young male Balb/c mice subjected to CLP. Varions physiological and organ injury marker levels: 
alkaline phosphatase (ALP), alanine aminotransferase (ALT), amylase (AMY), plasma glucose (GLU), plasma calcium (CA++), plasma phosphate (PHOS), plasma 
blood urea nitrogen (BUN), plasma creatinine (CRE), plasma sodium (Na+), plasma potassium (Na+), plasma albumin (ALB) and plasma globulin (GLOB) measured 
by Vetscan analysis, are shown in sham mice (not subjected to CLP) ("Sham"), in vehicle-treated mice subjected to CLP for 24 h ("CLP") and in mice subjected to CLP in 
the presence of varions doses of olaparib ("CLP Olaparib 1 mg/kg", CLP Olaparib 3 mg/kg" and "CLP Olaparib 10 mg/kg"). Data are shown as mean ± SEM of 10 
animais for each group; *p < 0.05 shows significant increase in the respective parameter in response to CLP, compared to the sham group; #p < 0.05 shows 
significant protective effect of olaparib in CLP mice compared to vehicle-treated CLP mice. 
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Fig. 3. Effect of olaparib on histological alterations injury in the lungs ofyoung male Balb/c mice subjected to CLP. Representative histological pictures are shown in 
sham mice (not subjected to CLP) ("Sham"), in vehicle-treated mice subjected to CLP for 24h ("CLP") and in mice subjected to CLP in the presence ofvarious doses of 
olaparib (''CLP Olaparib 1 mg/kg'', CLP Olaparib 3 mg/kg" and "CLP Olaparib 10 mg/kg'1. Pictures are selected fro m n = 5 animais for each group. 
Fig. 4. Effect of olaparib on histological alterations injury in the liver ofyoung male Balb/c mice subjected to CLP. Representat ive histological pictures are shown in 
sham mice (not subjected to CLP) ("Sham"), in vehicle-treated mice subjected to CLP for 24 h ("CLP") and in mice subjected to CLP in the presence ofvarious doses of 
olaparib ("CLP Olaparib 1 mg/kg", CLP Olaparib 3 mg/kg" and "CLP Olaparib 10 mg/kg'1. Pictures are selected from n = 5 animais for each group. 
2.2. Cecal ligation and puncture (CLP) 
Acute sepsis was induced in mice by cecal ligation and puncture as 
previously described (22]. Briefly, mice were anesthetized by 
ketamine/xylazine cocktail (i. p.), the abdomen was shaved, wiped with 
70% isopropanol and a midline abdominal incision (1-2 cm) was per-
formed. The cecum was exteriorized, ligated with a sterile silk suture 
1 cm from the tip and double punctured with a 20-gauge needle. The 
Fig. 5. Effect of olaparib on histological alterations in jury in the spleen ofyoung male Balb/c mi ce subjected ta CLP. Representative histological pictures a re show n in 
sham mice (not subjected to CLP) ("Sham"), in vehicle-treated mice subjected to CLP for 24h ("CLP") and in mice subjected to CLP in the presence ofvarious doses of 
olaparib ("CLP Olaparib 1 mg/kg", CLP Olaparib 3 mg/kg" and "CLP Olaparib 10 mg/kg'1. Pictures are selected from n = 5 animais for each group. 
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cecum was squeezed to assure expression of a small amount of fecal 
material and returned to the abdominal cavity. The incision was closed 
with auto-clips and kept clean by povidone-iodine (Betadine). Mice 
were resuscitated with intraperitoneal injection of 1 ml of lactated 
Ringer's solution. Sham-operated mice were treated as described above 
with the exception of ligation and puncture of the cecum. Buprenor-
phine (0.1 mg/kg; s.c. 30 min before surgery and every 12 h thereafter) 
was used for pain management. A sample of whole blood was collected 
for analysis of organ function using a comprehensive metabolic panel or 
for circulating mediator measurements using a multiple array system. 
Major organs were collected and either analyzed for immune cells by 
flow cytometry or snap frozen and kept at -80 'C until subsequent use 
(measurement of DNA integrity or MDA or MPO levels) or placed in 
formalin and processed for histological analysis. 
For the survival study, mice were constantly monitored for 48 h. 
Mice that survived this period of time were euthanized by cervical 
dislocation. All animal procedures described in this study have been 
approved by the respective local Institutional Animal Care and Use 
Committee of the University of Texas Medical Branch and the 
University of Sao Paulo. 
2. 3. Olaparib treatment protocol 
Ail groups of mice received the following intraperitoneal treatment: 
vehicle (phosphate-buffered saline [PBS] with 4% dimethyl sulfoxide 
[DMSOJ and 5% polyethylene glycol [PEG]); olaparib, 1 mg/kg, 3 mg/ 
kg or 10 mg/kg (dissolved in PBS with 4% DMSO 5% and PEG). In the 
24 -h protocol, the animais received two doses of olaparib, the first 
30 min after the CLP and the second 8 h after CLP, and the experiment 
was terminated at 24 h. In the survival protocol, treatment with the 
PARP inhibitor was initiated at 30 min after the CLP, the second dosing 
was performed at 8 h after CLP, and the same dosing was repeated 
subsequently every 8 h. Animais were monitored for 48 h at which time 
point the experiment was terminated. 
2.4. Complete membolic panel 
Samples of whole blood were collected from septic mice, placed in 
lithium-heparin tubes and immediately processed for the measurement 
of alanine aminotransferase (ALT), albumin (ALB), alkaline phospha-
tase (ALP), amylase (AMY) total calcium (Ca2 +), creatinine (CRE), 
glucose (GLU), phosphorus (PHOS), potassium (K + ), sodium (Na+), 
total bilirubin (TBIL), total protein (TP), and urea nitrogen (BUN) using 
the VetScan Chemistry Analyzer system (Abaxis) [ 22]. 
2. 5. Detection of circulating mediators 
Blood from CLP or sham-operated mice was collected in K2EDTA 
blood collection tubes and centrifuged at 4 ' C for 15 min at 2,000xg 
within 30 min of collection. Plasma was isolated, aliquoted and stored 
a t - 80 ' C until use. The EMD Millipore's MILLIPLEX™ MAP Mo use 
cytokine Magnetic Bead Panel 1 was used as described [22] for the 
simultaneous quantification of the following analytes: TNFa, IL-la, IL-
1[3, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12(p40), IL12(p70), 
IL-13, IL-15, IL-17, LIF, LIX, eotaxin, G-CSF, GM-CSF, KC, IP-10, MCP-1, 
RANTES, VEGF, MIP-la, MIP-1[3, MIP-2, M-CSF, MIG and IFNy. Data 
were processed using the Luminex xPONENT"' acquisition software. 
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Fig. 6. Effect of olaparib on the survival rate of young male Balb/c mice sub-
jected to CLP. Survival rates are shown in mice subjec ted to CLP in the presence 
of various doses of olaparib ("CLP Olaparib 1 mg/kg", CLP Olaparib 3 mg/kg" 
and "CLP Olaparib 10 mg/kg") . Data are shown as mean ± SEM of 10-12 an-
imais for each group; #p < 0.05 shows significant protective effect of olaparib 
in CLP mice compared to vehicle-trea ted CLP mice. 
2. 6. Determination of tissue lipid peroxidation: malon dialdehyde assay 
Tissue malon dialdehyde (MDA) levels, an index of cellular injury/ 
oxidative stress, were measured as descr ibed [22] in tissue homo-
genates from mice subj ected to 24h of CLP-induced sepsis, using a 
fluorimetric MDA-specific lipid peroxidation assay kit (Enzo Life Sci-
ences). 
2. 7. Myeloperoxidase activity assay 
Myeloperoxidase activity was measured as described [22] in tissue 
homogenates from mice subjected to 24 h of CLP-induced sepsis, using a 
commercially available MPO fluorometric detec tion kit (Enzo Life Sci-
ences). 
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Fig. 7. Effect of olaparib on Jung, liver and spleen mitochondrial DNA integrity, mitochondrial DNA copy number and nuclear DNA integrity in young male Balb/c 
mice subjected to CLP. (A): Lung mitochondrial DNA integrity, mitochondrial DNA copy number and nuclear DNA integrity values (expressed as% of control); (B): 
liver mitochondrial DNA integrity, mitochondrial DNA copy number and nuclear DNA integrity values (expressed as% of control); (C) spleen mitochondrial DNA 
integrity, mitochondrial DNA copy number and nuclear DNA integrity values (expressed as% of control) are shown in sham mice (not subjected to CLP) ("Sham"), in 
vehicle-treated mice subjected to CLP for 24 h ("CLP") and in mice subjected to CLP in the presence of varions doses of olaparib ("CLP Olaparib 1 mg/kg", CLP 
Olaparib 3 mg/kg" and "CLP Olaparib lOmg/kg"). Data are shown as mean ± SEM of 10 animais for each group; *p < 0.05 shows significant change in a respective 
parameter in response to CLP, compared to the sham group; #p < 0.05 shows significant effect of olaparib on a given parameter in CLP mice compared to vehicle-
treated CLP mice. 
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Fig. 9. Effect of olaparib on E. coli bacterial growth in vitro. Data show bacterial 
numbers at various time points in vehicle-treated group, and in the groups of 
bacteria in the presence or various concentrations (1, 3, 10, 30, 100 µM) ola-
parib for various time points (1- 5 h). Data are shown as mean ± SEM of 5 
determinations per group. 
2.8. M eas!ffement of nuclear Wld mitochondrial DNA integrity 
Integrity of the nuclear and mitochondrial DNA, measured by the 
relative amount of DNA damage, was analyzed by semi-quantitative, 
long-amplicon PCR assays (LA-PCR) using LongAmp Taq DNA 
Polymerase (New England BioLabs, Ipswich, MA) in tissue homogenates 
as described [ 23]. Total DNA was isolated using DNase Blood and 
Tissue Kit (QIAGEN, Hilden, Germany). Briefly, damage to nuclear DNA 
was estimated by quantification of the PCR amplification of the 
10 kb nuclear-specific DNA fragment using PicoGreen fluorescent dye to 
detect amplified double-stranded DNA (Quant-iT™ PicoGreen; Life 
Technologies, Carlsbad, CA). Damage to the mitochondrial DNA was 
estimated by quantification of the PCR amplification of the 8.9 kb 
mitochondrial-specific DNA fragment using PicoGreen staining. Data 
were normalized by the secondary PCR amplification of 221 bp mi-
tochondrial genome-specific fragment for correction of the multiple 
copies of the mitochondrial DNA. LA-PCR assay is based on premises 
that DNA damage inhibits progression of DNA polymerase during PCR 
reaction and thus amplification of appropriate DNA fragment is nega· 
tively correlated with the level of the DNA damage. 
3000 108 
107 
'tl ; 106 
0 2000 Cl) 0 Ci. 10• 
:;:; 
"' Ë ~ !!! 104 3 1000 ~ 103 u. (J (J 102 101 0 10° 
CLP CLP 'CLP olaparib 
10 mg/kg 
2. 9. Determination of colony-forming bacterial units (CFUs) after sepsis or 
bacteremia 
Blood was diluted serially in sterile saline. Spleen was homogenized 
in sterile saline at 100 mg tissue/ ml concentration followed by serial 
dilution. Fifty microliters of each dilution was plated and cultured on 
LB agar plates at 37 °C. After 16 h of incubation, the number of bacterial 
colonies was counted and expressed as CFUs per milliliter of blood or as 
CFUs per milligram or gram tissue. 
In an in vitro satellite experiment, we evaluated whether olaparib 
has any direct effect on bacterial growth. In these exper iments DHSa 
Rcoli were cultured in liquid LB growth medium in a shaking incubator 
set to 37 °C and 200 RPM in the presence of various concentrations 
(1-1 OO µM) of olaparib. The culture density was measured a t OD60o 
over 5 h. 
In an in vivo satellite experiment, we evalua ted whether ola parib has 
any direct effect on bacterial clearance in vivo in the absence of septic 
shock. Male C57BL6 mice (8 weeks old) were obtained from J ackson 
Laboratories. Animals (either treated with olaparib, 10 mg/kg i. p. at 
30 min and 8 h post-inoculation, or treated with corresponding vehicle 
control) were injected with 3 x 108 CFU DHSa E. coli i. p. and tissues 
harvested 20 h post-infection. CFUs in blood, spleen and liver were 
quantified as described above. 
2.1 O. Histological Wlalysis 
Tissues were fixed for 1 week in buffered formaldehyde solution 
(10% in PBS) at room temperature, dehydrated by graded ethanol and 
embedded in Paraplast (Sherwood Medical, Mahwah, NJ, USA). Tissue 
sections (thickness: 7 µm) were deparaffinized w ith xylene stained with 
hematoxylin/eosin and stud ied using light microscopy. Slides were 
evaluated in a blinded fashion. 
2.11. Row cytomeoy 
For phenotypic characterization of cells by flow cytometry from 
spleen and blood samples, we performed three panels: T cells (panel 1 ), 
Treg cells (panel 2) and Thl 7 cells (panel 3). Cell suspensions were 
prepared and were re-suspended in flow cytometry buffer (PBS 
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Fig. 10. Effect of olaparib on blood, spleen and liver bacterial colony-forming unit (CFU) numbers in young male Balb/c mice subjected to E. coli bacteria in vivo. 
Blood (expressed as CFU/ml), spleen and liver CFUs (expressed as CFU/ g) are shown in vehicle-treated mice inocula ted w ith E. coli for 24 h ("CLP '1 and in mice 
subjected to CLP in the presence of 10 mg/kg olaparib. Data are shown as mean ± SEM of 6 animais for each group. 
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Fig. 11. Effect of olaparib on the levels of varions circulating mediators (cytokines, chemokines, growth factors) in young male Balb/c mice subjected to CLP. Values 
are shown in sham mice (not subjected to CLP) ("Sham"), in vehicle-treated mice subjected to CLP for 24 h ("CLP") and in mice subjected to CLP in the presence of 
varions doses of olaparib ("CLP Olaparib 1 mg/kg", CLP Olaparib 3 mg/kg" and "CLP Olaparib 10 mg/kg"). Data are shown as mean ± SEM of 10 animais for each 
group; *p < 0.05 shows significant increase in the respective parameter in response to CLP, compared to the sham group; #p < 0.05 shows significant protective 
effect of olaparib in CLP mice compared to vehicle-treated CLP mice. 
8
ht
tp
://
do
c.
re
ro
.c
h
Spleen 
cO 
0 
1.5x1Q 09 
() 1.0•10 09 
~ 
0 
() 
(!; 5.0x1Q 08 
0 
() 
+ ~ 2.ox10°1 
)( 
0 
u.. 1.sx10°1 
il; 
"' 8 1.0•1007 
+ i?i 5000000.0 
() 
0 
* 
# 
8.0• 1008 
+ ~ 6.0x10°8 
() 
~ 4.0x10°8 
() 
+ M 
0 2.0•10°' 
() 
.1 1.5•10 07 
.... 
~ 
~ 1.0•10 07 
~ 
+ ~ 5000000.0 
0:: 
~ 
# 
0 
+ ., 
6.0x10°8 
8 4.0• 1008 
~ 
() 
(!; 2.ox10°8 
0 
() 
0.8 
0.6 
Cl 
~ 
~ 0.4 
.<: 
1-
0.2 
* 
0 
# 
8 o .o~~~~~~~- .O.J._-'--~--'-----L-~----J'----
200000000 
+ 150000000 
Ci () 100000000 
50000000 
0 
0 
* 
+ 
"' Ci 
() 
0 
Fig. 12. Effect of olaparib on the numbers ofvarious T-cell populations in the spleen ofyoung male Balb/c mice subjected to CLP. Values are shown in sham mice 
(not subjected to CLP, but treated with vehicle for 24 h) ("V"), in sham mice (not subjected to CLP, but treated with 10 mg/kg olaparib for 24 h) ("O") in vehicle-
treated mice subjected to CLP for 24 h ("CLP-V") and in mice subjected to CLP in the presence of 10 mg/kg olaparib ("CLP-0"). Data are shown as mean ± SEM of 10 
animais for each group; *p < 0.05 shows a significant change in the respective cell population in comparison to the sham group; #p < 0.05 shows significant effect 
of olaparib under non-CLP conditions (compared to vehicle-treated sham mice) or in CLP mice (compared to vehicle-treated CLP mice). 
containing 2% BSA). Cells were stained with anti-CD3, CD4, and CDS 
(panel 1), anti-CD4, CD25 (panel 2) and anti-CD4 (panel 3) antibodies 
for 30 min in dark at 4 'C than were washed twice with flow cytometry 
buffer. For panel 1, cells were collected and analyzed by flow cyto-
metry. Additionally, macrophages, B cells and neutrophils were simi-
larly analyzed using antibodies against CDllb, CD19, and Ly6G. For 
panels 2 and 3, cells which were stained with surface markers were 
fixed and permeabilized with eBioscience's Permealization Kit, then 
incubated with anti-Foxp3 (panel 2) and anti-RORy, IL-17 A and IL-17 F 
(panel 3) antibodies for 30 min in the dark at 4 'C. Cells were then 
washed and analyzed by flow cytometry (Guava 8 H T; Merck-
Millipore). 
2.12. RT-PCR studies of miRNA expression 
Total RNA was extracted from spleen and white blood cells using 
Trizol reagent (Invitrogen Carlsbad, California, EUA) according to the 
manufacturer's specifications. Extracted RNA was eluted in RNase-free 
water, treated with DNase I, Amplification Grade (ThermoFisher, 
Waltham, MA, USA) according to the manufacturer's specifications and 
quantified by spectrophotometry. 
cDNA was synthesized using miScript II RT Kit (Qiagen - Hilden, 
Germany) using HiSpec buffer chemistry, which exclusively reverse 
transcribes mature miRNA to cDNA; this mixture was incubated for 
60 min at 37 'C and for 5 min at 95 'C to inactivate miScript Reverse 
transcriptase mix and placed on ice. 
A functional quality contrai was performed on cDNA samples using 
miScript miRNA QC PCR array. qPCR was performed on a StepOnePlus 
Real-Time PCR System (ABI, Poster City, California, EUA). Threshold 
cycles (C) for PPC and RT contrai (miRTC) were examined to assess PCR 
and RT efficiencies, respectively. The expression of cel-miR-39 assay 
was also observed to confirm efficient RNA recovery. C values for all 
contrais were within the manufacturer's recommended range for a 
successful quality contrai (QC). 
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Fig. 13. Effect of olaparib on the percentages ofvarious T-cell populations in the spleen ofyoung male Balb/c mice subjected to CLP. Values are shown in sham mice 
(not subjected to CLP, but treated with vehicle for 24 h) ("V"), in sham mice (not subjected to CLP, but treated with 10 mg/kg olaparib for 24 h) ("0 '') in vehicle-
treated mi ce subjected to CLP for 24 h ("CLP-V") and in mi ce subjected to CLP in the presence of 10 mg/kg olaparib ("CLP-0 "). Data are shown as mean ± SEM of 10 
animais for each group; *p < 0.05 shows a significant change in the respective cell population in response to CLP, compared to the sham group; # p < 0.05 shows 
significant effect of olaparib under non-CLP conditions (compared to vehicle-treated sham mice) or in CLP mice (compared to vehicle-treated CLP mice). 
Large-scale analysis of miRNA expression was performed using 
miScript miRNA PCR Array Mouse Apoptosis (96 well format) (Qiagen -
Hilden, Germany). 12 plaques per organ were made. A set of controls 
are included on each plate which enables data analysis using AACT 
method of relative quantification, assessment of reverse transcription 
performance, and assessment of PCR performance. The miScript miRNA 
PCR array enables SYBR Green-based real-time PCR analysis using 
StepünePlus Real-Time PCR System (ABI, Foster City, California, EUA) 
as follows: for 15 min at 95 °C; 40 cycles of 15 s at 94 °C; for 30 s at 
55 °C; and for 30 s at 70 °C and its software determined the number of 
copies of each gene from the microarray plates. 
Values of miRNA expression were normalized using the geomettic 
mean calculated from the internal control genes classified according to 
RetFinder Software and fold changes were calcula ted by the 2 - MCT 
method. The analysis of the array was performed by the software 
available in SaBiosciences' Data Analysis Center (https://www.qiagen. 
corn/br/ shop/ genes-and-pa thwa ys/ da ta -analysis-center-overview-
page/). The most significantly altered miRNAs were confirmed by RT-
PCR. The altered miRNAs miR-15a-5p, miR-17-5p, miR-146a-5p and 
miR-365-3p that were chosen for confirmation from the array; the 
primers were purchased from Qiagen. The cDNA was synthesized using 
miScript II RT Kit and the PCR was performed using miScript SYBR 
Green PCR Kit. Again, the values of miRNA expression were normalized 
using the geomettic mean calculated from the previously internal 
control genes classified and fold changes were calculated by the 
2 - MCT method. 
2.13. In vitro srudies in U937 cells subjected ro oxida.tive stress 
Human monocyte histiocytic lymphoma cells (U937) were obtained 
from ATCC and maintained in RPMI1640 with 10% fetal bovine serum 
(Life Technologies). For resazurin and LDH assays, U937 cells were 
plated in 96-well plates at 2 x 104 cells/well. For DNA integrity, U937 
cells were plated in 12-well plates at 2 x 105 cells/ well. For the NAD+ 
quantification assay, U937 cells were plated in 12-well plates at 
3 x 105 cells/well. 
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Fig. 14. Effect of olaparib on the numbers of varions T-cell populations in the blood of young male Balb/c mice subjected to CLP. Values are shown in sham mice (not 
subjected to CLP, but treated with vehicle for 24 h) ("V"), in sham mice (not subjected to CLP, but treated with 10 mg/kg olaparib for 24 h) ("O") in vehicle-treated 
mice subjected to CLP for 24 h ("CLP-V") and in mice subjected to CLP in the presence of 10 mg/kgolaparib ("CLP-0"). Data are shown as mean ± SEM of 10 animais 
for each group; *p < 0.05 shows a significant change in the respective cell population in response to CLP, compared to the sham group; #p < 0.05 shows significant 
effect of olaparib under non-CLP conditions (compared to vehicle-treated sham mice) or in CLP mice (compared to vehicle-treated CLP mice). 
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Fig. 15. Effect of olaparib on the percentages ofvarious T-cell populations in the blood ofyoung male Balb/c mice subjected to CLP. Values are shown in sham mice 
(not subjected to CLP, but treated with vehicle for 24 h) ("V"), in sham mice (not subjected to CLP, but treated with 10 mg/kg olaparib for 24 h) ("O") in vehicle-
treated mice subjected to CLP for 24 h ("CLP-V") and in mice subjected to CLP in the presence of 10 mg/kg olaparib ("CLP-0"). Data are shown as mean ± SEM of 10 
animais for each group; *p < 0.05 shows a significant change in the respective cell population in response to CLP, compared to the sham group; #p < 0.05 shows 
significant effect of olaparib under non-CLP conditions (compared to vehicle-treated sham mice) or in CLP mice (compared to vehicle-treated CLP mice). 
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Fig. 16. Effect of olaparib on spleen and blood T-cell miRNA levels in young male Balb/c mice subjected to CLP. Values are shown in sham mice (not subjected to 
CLP, but treated with vehicle for 24 h) ("V"), in sham mi ce (not subjected to CLP, but treated with 10 mg/kg olaparib for 24 h) ("0'') in vehicle-treated mi ce subj ected 
to CLP for 24 h ("CLP-V'') and in mice subjected to CLP in the presence of 10 mg/kg olaparib ("CLP-0''). Data are shown as mean ± SEM of 10 animais for each group; 
*p < 0.05 shows a significant change in the respective miRNA level in response to CLP, compared to the sham group; # p < 0.05 shows significant effect of olaparib 
under non-CLP conditions (compared to vehicle-treated sham mice) or in CLP mice (compared to vehicle-treated CLP mice). 
Cells were differentiated with PMA (100 ng/ml for 48 h), then 
subjected to various concentrations of hydrogen peroxide (H20 2, 300 
µM, 600 µM, 1 mM) for 1 h, in the presence or absence of olaparib (1, 3, 
10, 1 OO µM) pretreatment. After 1 h, cell viability was measured with 
the resazurin (7-hydroxy-3H-phenoxazin-3-one 10-oxide) method, or 
cell necrosis was detected by measuring the release of lactate dehy-
drogenase (LDH) to the culture medium as described [ 24]. Mitochon-
drial and nuclear DNA integrity was measured with the LA-PCR method 
as described above. Poly-ADP-ribose polymerase-1 (PARPl) enzyme 
and its product, poly-ADP-ribose (PAR) and actin (a loading control) 
were detected by Western blotting as described [25]. Total cellular 
NAD+ was determined using NAD/NADH Quantification Kit (Sigma) 
according to the manufacturer's protocol. The amount of NAD+ present 
in the samples was quantified in a colorimetric assay, measured at 
450 nm using a microplate reader. The amount of NAD+ was normal-
ized to protein content of the samples, quantified using the PierceTM 
BCA Protein Assay. 
Cellular bioenergetics was measured by the Extracellular Flux 
Analysis method as described [26]. Briefly, cells were seeded on cell 
culture microplates (60,000/well). After 24 h, cells were pretreated 
with olaparib (1, 3 or 10 µM) or its vehicle for 30 min, followed by 
exposure to H20 2 (300 µM) for 1 h. For analysis of mitochondrial re-
spiration, cells were washed twice with DMEM medium pH 7.4 sup-
plemented with L-glutamine (2 mM, Gibco), sodium pyruvate (1 mM, 
Sigma) and glucose (10 mM, Sigma). After 1 h incubation at 37 °C in 
C02-free incubator, the oxygen consumption rate (OCR) after oligo-
mycin (1 µM) was used to assess ATP production rate and the OCR after 
carbonyl cyanide-4-trifluoromethoxy phenylhydrazone (FCCP, O. 7 µM) 
to assess maximal mitochondrial respiratory capacity. Antimycin A (0.5 
µM) and rotenone (0.5 µM) were used to inhibit the flux of electrons 
through complex III and I, to detect residual non-mitochondrial OCR, 
which is considered to be due to cytosolic oxidase enzymes. For analysis 
of glycolytic parameters, cells were treated with olaparib and H20 2 (as 
above), washed twice with phenol red -free DMEM medium pH 7.4 
containing L-glutamine (2 mM), sodium pyruvate (1 mM), glucose 
(10 mM) and HEPES (5 mM, Sigma). After 1 h incubation at 37 °C in 
C02-free incubator, proton efflux rate (PER) from basal and compen-
satory glycolysis was measured. Mitochondria inhibition by rotenone 
(0.5 µM) and antimycin A (0.5 µM) allows calculation of the 
mitochondrial-associated acid ification. Subsequently, 2-deoxy-o-glu-
cose (50 mM) was used to inh ibit glycolysis and stop glycolytic acid-
ification. Glycolytic proton efflux rate (glycoPER) was calc ulated by 
subtracting the mitochondr ial acidification to the total PER. All the 
results were normalized by total protein. 
2.14. Stxitistical analysis 
Data are shown as mean ± SEM. One-way and two-way ANOVA 
with Bonferroni's multiple comparison test were used to detect differ-
ences between groups. Two main type of comparisons were performed. 
The first type was to determine whether the insult (CLP in vivo or oxi-
dative stress in vitro) has an effect on a given parameter compared to 
normal control values (animals not subjected to CLP or cells not sub-
jected to H20 2). Statistically significant differences between these two 
groups are indicated by *p < 0.05 or **p < 0.01. The second type 
was to detect if olaparib affected the response in the groups that were 
subjected to the insult (CLP in vivo or oxidative stress in vitro), com-
pared to the groups that were subjected to the same insults in the ab-
sence of olaparib (Le. in the presence of olaparib vehicle). Statistically 
significant differences between these two groups are indicated by 
#p < 0.05 or ##p < 0.01. Survival differences were analyzed by the 
Chi square test. Statistical calculations were performed using Graphpad 
Prism analysis software. 
3. Results 
3.1. Olaparib exern organ protective and anti-infiammatory eff ects in 
organs of young adult male mice subjected to CLP, without adverse/y 
affecting D NA integrity 
In young adult male mi ce subjected to CLP, olapar ib (1 , 3 or 10 mg/ 
kg i.p.) concentration-dependently improved several parameters of 
multiorgan dysfunction (Figs. 1-3). For instance, the CLP-induced in-
creases in spleen MPO content and liver and spleen MDA levels were 
attenuated by olaparib (Fig. 1) . In addition, the CLP-induced increases 
in plasma markers ofliver and pancreas inj ury (ALP, ALT, amylase) and 
renal dysfunction (BUN) were attenuated by olaparib treatment 
(Fig. 2). The histopathological pictures of the lungs d id not show 
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Fig. 17. Effect of olaparib on selected parameters of organ injury in young female Balb/c mice subjected to CLP. Various physiological and organ injury marker 
levels: alkaline phosphatase (ALP), alanine aminotransferase (ALT), amylase (AMY), plasma glucose (GLU), plasma calcium (CA+ +), plasma phosp hate (PHOS), 
plasma blood urea nitrogen (BUN), plasma creatinine (CRE), plasma sodium (Na+), plasma potassium (Na+), plasma albumin (ALB) and plasma globulin (GLOB) 
measured by Vetscan analysis, are shown in sham mice (not subjected to CLP) ("Sham''), in vehicle-treated mice subjected to CLP for 24 h ("CLP") and in mice 
subjected to CLP in the presence of various doses of olaparib ("CLP Olaparib 1 mg/kg", CLP Olaparib 3 mg/kg" and "CLP Olaparib 10 mg/kg"). Data are shown as 
mean ± SEM of 10 animais for each group; *p < 0.05 shows significant increase in the respective parameter in response to CLP, compared to the sham group. 
marked alterations in any of the groups, with slight emphysema evident 
in ail a,p groups (Fig. 3). In the liver, foamy degeneration of numerous 
hepatocytes is evident in the CLP group; olaparib, at the 10 mg/kg dose, 
normalized the morphology of the hepatocytes (Fig. 4). In the spleen, 
CLP induced macrophage infiltration, and evidence of hemolysis was 
evident, with no marked differences between CLP groups with or 
without olaparib (Fig. 5 ). 
Olaparib, at 10 mg/kg (but not at the two lower doses used), caused 
a significant prolongation of survival of the animals subjected to ap 
(Fig. 6). 
CLP did not induce detectable damage in nuclear DNA in any of the 
organs (liver, lung, spleen) studied, but in the liver, a significant degree 
of mitochondrial DNA damage was detected, which was prevented by 
olaparib treatment (Fig. 7). Olaparib treatment reduced the number of 
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bacteria in the plasma and spleens of mice subjected to CLP (Fig. 8). 
However, this effect does not appear to be a direct antibacterial action 
of olaparib, as in vitro incubation of E. coli with various concentrations 
of olaparib (1-1 OO µM) did not have any effect on bacterial growth 
(Fig. 9). Moreover, in a satellite experiment of bacteremia without 
septic shock, olaparib treatment failed to significantly affect bacterial 
CFUs in the blood, spleen or liver after an i.p. bolus of E. coli (Fig. 10). 
Olaparib treatment in the CLP model attenuated the increases in the 
levels of several circulating mediators in the plasma (e.g. 1NFa, IL-la, 
IL-1 [3, IL-2, IL-4, IL-6, IL-l 2p40), while others (e.g. IL-1 O,RAN1ES, 
VEGF) were unaffected (Fig. 11 ). 
In the spleen, the number of CD4 + and CD8 + lymphocytes were 
reduced in response to CLP; this reduction was attenuated by olaparib 
treatment (Fig. 12). Moreover, in the spleen, the number of Treg 
(CD4 + CD25 + FoxP3 +) but not Thl 7 (CD4 + RORy +ILI 7 A+ ILI 7F 
+) lymphocytes increased in response to CLP; the number, as well as 
percentage of both of these cell populations were reduced in CLP when 
the animals also received olaparib (Fig. 12,13). The number of 
CDll b + cells in spleen were significantly decreased by CLP, but per-
centages were significantly increased; olaparib had no significant effect 
on these responses. The number of CDl 9 + cells were significantly 
decreased by CLP and not affected by olaparib, and numbers and per-
centages of neutrophils were unaffected by CLP and olaparib (Figs. 12 
and 13). 
CLP reduced the number of Thl 7 cells in the blood - but increased 
as a percentage, since these alterations in Thl 7 cell numbers occur 
against the background of an overall lymphopenia - and the number (as 
well as percentage) of these cells was further reduced by olaparib 
(Figs. 14 and l5 ). The Thl7/Treg ratio is related to SOFA score; ele-
vated ratios have been associated with increases in SOFA scores, an 
indication of organ damage [27]. In the spleen, this ratio was sig-
nificantly lower in CLP/olaparib group than in the CLP/vehicle group 
(Fig. 12) and slightly lower in the blood, although not significantly 
(Fig. 14). 
CFU SPLEEN 
• 1 
• 
• 
CLP CLP 
Olaparib 
(10 mg/kg) 
Fig. 18. Effect of olaparib on blood and spleen 
bacterial colony-fonning unit (CFU) numbers 
in young female Balb/ c mice subjec ted to CLP. 
(A): Blood CFUs (expressed as CFU/ ml) and (B) 
spleen CFU s (expressed as CFU/ml) are show n 
in vehicle-treated mice subjected to CLP for 
24 h ("CLP") and in mice subjected to CLP in 
the presence of 10 mg/kg olaparib ("CLP 
Olaparib 10 mg/kg"). Data are shown as 
mean ± SEM of 10 animais for each group. 
In recent years, miRNAs have been identified as important reg-
ulators of a host of immune (as well as parenchymal) cell functio ns, 
with each miRNA playingvarious regulatory roles that are context- and 
cell-type as well as pathophysiological condition dependent. Large-
scale analysis of miRNA expression identified a multitude of changes in 
splenic miRNA levels after CLP; olaparib treatment attenuated the CLP-
induced alterations in miR15, miRl 7, miR181 and miR365 and levels 
(Fig. 16). For miRl 46, in the spleen, olaparib attenuated its CLP-in-
duced downregulation, while in the circulating leukocytes, olaparib 
enhanced its CLP-induced upregulation (Fig. 16 ). 
3.2. The beneficial effects of olaparib are absent in yowig adult female mice 
subjected to CLP 
In contrast to the findings in male mice, in young adult female mice 
subjected to CLP, olaparib (10 mg/kg i.p .) did not attenuate b lood or 
splenic CFUs and did not have any significant effect on the various 
circulating markers of organ injury (Figs. 17 and 18). This finding 
confirms prior data showing that PARP inhibitors preferentially exert 
their beneficial effects in male animals subjected to var ious forms of 
critical illness (as overviewed in [1 9]). The degree of the change in 
several circulating markers (e.g. amylase, BUN) of injury in female mice 
tended to be less pronounced in female mice than in male mice after 
CLP (Fig. 2 vs. Fig. 17), perhaps indicating a lesser degree of baseline 
CLP-induced multiple organ injury in female mice versus male mice. 
3.3. Olaparib exerts beneficial effects on some parameters ofinjury in ggfil 
male and female mice subjected to CLP 
Since septic shock is, to a large extent, a disease of the elderly [1,2], 
and since in aged organisms some of the pathophysiological mechan-
isms are not only quantitatively but also qualitatively different from the 
mechanisms that occur in young adult organisms [2,22,28- 30], we 
have also investigated the effect of olapar ib in aged mice (72 weeks old 
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Fig. 19. Effect of olaparib on selected parameters of organ injury in aged male Balb/ c mice subjected to CLP. Various physiological and organ injury marker levels: 
alkaline phosphatase (ALP), alanine aminotransferase (ALT), amylase (AMY), plasma glucose (GLU), plasma calcium (CA++ ), plasma phosphate (PHOS), plasma 
blood urea nitrogen (BUN), plasma creatinine (CRE), plasma sodium (Na+), plasma potassium (Na+), plasma albumin (ALB) and plasma globulin (GLOB) measured 
by Vetscan analysis, are shown in sha m mice (not subjected to CLP) ("Sha m''), in vehicle-treated mi ce subjected to CLP fo r 24 h ("CLP'') and in mi ce subjec ted to CLP in 
the presence of various doses of olaparib ("CLP Olaparib 1 mg/kg", CLP Olaparib 3 mg/kg" and "CLP Olaparib 10 mg/kg"). Data are shown as mean ± SEM of 10 
animais fo r each group; *p < 0.05 shows significant increase in the respective parameter in response to CLP, compared to the sham group; # p < 0.05 shows 
significant effect of olaparib in CLP mice (compared to vehicle-treated CLP mice). 
males and in females). Surprisingly, - with the exception of the pan-
creatic injury marker amylase - olaparib exetted no significant bene-
ficial effects on most organ injury markers in aged male mice (Fig. 19) 
and only had modula tory effects on a small subset of circulating med-
iators: IL-4 and IL-l 2(p70) (Fig. 20). 
In contrast, in aged female mice, olapar ib trea tment significantly 
reduced the CLP-induced liver injury markers ALP and ALT (Fig. 21). 
However, levels of the kidney injury marker BUN and pancreatic 
marker amylase were not affected by olaparib after injury. Circulating 
levels of the CLP-induced mediators TNFa, IL- l a, MIPla, M-CSF and 
MIG were significantly reduced by olaparib trea tment (Fig. 22) . 
Neither in aged male or female mice subjected to CLP did we ob-
serve any adverse effect of olaparib on nuclear or mitochondrial DNA 
integrity (Fig. 23). 
Overall, the degree of the beneficial effect of the PARP inhibitor 
tended to be less pronounced in the aged mice than in the young male 
mice (Figs. 1-2. vs. Figs. 17-22). 
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Fig. 20. Effect of olaparib on the levels ofvarious circulating mediators (cytokines, chemokines, growth factors) in aged male Balb/c mice subjected to CLP. Values 
are shown in sham mice (not subjected to CLP) ("Sham"), in vehicle-treated mice subjected to CLP for 24 h ("CLP") and in mice subjected to CLP in the presence of 
10 mg/kg olaparib ("CLP Olaparib 10 mg/kg"). Data are shown as mean ± SEM of 10 animais for each group; *p < 0.05 shows significantincrease in the respective 
parameter in response to CLP, compared to the sham group; #p < 0.05 shows significant protective effect of olaparib in CLP mice compared to vehicle-treated CLP 
mice. 
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Fig. 21. Effect of olaparib on selected parameters of organ injury in aged female Balb/c mice subjected to CLP. Various physiological and organ injury marker levels: 
alkaline phosphatase (ALP), alanine aminotransferase (ALT), amylase (AMY), plasma glucose (GLU), plasma calc ium (CA ++ ), plasma phosphate (PHOS), plasma 
blood urea nitrogen (BUN), plasma creatinine (CRE), plasma sodium (Na+), plasma potassium (Na+), plasma albumin (ALB) and plasma globulin (GLOB) measured 
by Vetscan analysis, are shown in sham mi ce (not subjected to CLP) ("Sham''), in vehicle-treated mi ce subjected to CLP fo r 24 h ("CLP '') and in mi ce subjec ted to CLP in 
the presence of various doses of olaparib ("CLP Olaparib 1 mg/kg", CLP Olaparib 3 mg/kg" and "CLP Olaparib 10 mg/kg"). Data are show n as mean ± SEM of 10 
animais for each group; *p < 0.05 shows significant increase in the respective parameter in response to CLP, compared to the sham group; #p < 0.05 shows 
significant effect of olaparib in CLP mice (compared to vehicle-treated CLP mice). 
3.4. Olaparib exerts cytnprotective and beneficial bioenergetic effects in 
U937 cells suhjected to oxidative stress in vitro, without adverse/y affectiJJg 
DNA integrity 
In in vitro experiments in U937 cells subjected to oxidative stress, 
olaparib (1-100 µM) completely inhibited PARylation (as measured by 
the quantification of poly(ADP-ribose) [PAR], the product of the en-
zyme) already at the lowest concentration (1 µM) used, confirming the 
well-established [31] patent effect of olaparib to inhibit PARPl cata-
lytic activity (Fig. 24A). In line with prior findings demonstrating that 
PARP inhibition prevents the cellular depletion of its substrate, NAD+ 
[32,33], olaparib also protec ted against the H20 2-induced loss of cel-
lular NAD+ levels, with the effec ts already near-maximal at its lowest 
tested concentration (1 µM) (Fig. 24B,C). Consistent with prior findings 
demonstrating the protective effect of PARP inhibitors in cells exposed 
to various oxidants [25,32-35] olaparib protected against the H202· 
induced loss of cell viability, indicated by continued resazurin reduc-
tion in the presence of olaparib treatment (Fig. 25). The PARP inhibitor 
also protected against the H20 2-induced changes in oxidative phos-
phorylation · as assessed by cellular bioenergetic parameters such as 
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Fig. 22. Effect of olaparib on the levels of varions circulating mediators (cytokines, chemokines, growth factors) in aged female Balb/c mice subjected to CLP. Values 
are shown in sham mice (not subjected to CLP) ("Sham"), in vehicle-treated mice subjected to CLP for 24 h ("CLP") and in mice subjected to CLP in the presence of 
10 mg/kg olaparib ("CLP Olaparib 10 mg/kg"). Data are shown as mean ± SEM of 10 animais for each group; *p < 0.05 shows significantincrease in the respective 
parameter in response to CLP, compared to the sham group; #p < 0.05 shows significant protective effect of olaparib in CLP mice compared to vehicle-treated CLP 
mice. 
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Fig. 23. Effect of olaparib on liver mitochondrial DNA integrity, mitochondrial DNA copy number and nuclear DNA integri ty in aged male and female Balb/c mice 
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mice; (B): mitochondrial DNA integrity, mitochondrial DNA copy number and nuclear DNA integrity values (expressed as% of contrai) in aged female mice. Data are 
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kg olaparib ("CLP Olaparib 10 mg/kg"). Data are shown as mean ± SEM of 10 animais for each group. 
resting and FCCP-stimulated (maximal) mitochondrial respiration - as 
well as against the H202-induced changes in anaerobic respiration 
(glycolysis) (Figs. 26-29). 
At the entire concentration range tested (1-1 OO µM), olaparib did 
not have any adverse effects on nuclear or mitochondrial DNA integrity 
in control cells (le. cells not subjected to oxidative stress) (Fig. 30A) but 
protected against the development of oxidative stress-induced mi-
tochondrial DNA damage (Fig. 30B,C). This latter finding may be re-
lated to effects on the mitochondrial isoform of PARP, which has a 
qualitatively different role in the regulation of mitochondrial DNA re-
pair than its nuclear counterpart [36]. At the lower levels of oxidative 
stress - in line with prior observations [36-38] - the H20 rinduced DNA 
damage was preferential to mitochondrial, as opposed to nuclear DNA 
(Fig. 30B). At the highest concentration of H20 2 tested (1 mM), nuclear 
DNA damage was also detected: this damage, however, was not further 
exacerbated by olaparib (Fig. 30C). 
Taken together, we have demonstrated cytoprotective and positive 
bioenergetic effects of olaparib in oxidatively stressed U937 cells, but 
we did not find any adverse effect of the PARP inhibitor on DNA in-
tegrity. 
4. Discussion 
The overall conclusion of the current study is that in young male 
mice subjected to Œ,P the PARP inhibitor olaparib improves organ 
function, beneficially modulates the inflammatory and immune re-
sponse, and extends survival in septic shock. Moreover, all of these 
effects occur without any detectable adverse effects on mitochondrial or 
nuclear DNA integrity. The in vitro experiments, demonstrating cyto-
protective and beneficial cellular bioenergetic effects of olaparib - once 
again without any detectable adverse effects on mitochondrial or 
nuclear DNA integrity - are in line with the conclusions of the in vivo 
experiments. 
Prior studies have demonstrated multiple modes of PARP inhibitor's 
beneficial effects in various non-oncological models of cell and organ 
injury and local and systemic inflammation. These effects include direct 
cytoprotective actions (preserving NAD+ and ATP levels and thereby 
protecting against cell necrosis) [32,33,39]; suppression of the expres-
sion and production of multiple pro-inflammatory mediators and cir -
culating factors [ 40- 43]; prevention of the infiltration of organs with 
activated mononuclear and polymorphonuclear cells [33,44] and pro-
tection against the loss of vascular (especially endothelial) integrity 
[5-7,33]. Many of the cytoprotective and organ-protective effects of 
olaparib have also been d irectly demonstrated in various models, ran-
ging from neuroinjury to endotoxin-induced lung and kidney failure 
(reviewed in [19]). The current study confirms and extends these ob-
servations. However, the current study also demonstrates that not all 
populations of animals subjected to Œ,P benefit equally from olapar ib. 
Oearly, the most pronounced effects were noted in the young adult 
male mice. On the other hand, olaparib exer ted no significant benefit in 
young adult female mice subjected in CIP. This find ing is in line with 
several sets of studies demonstrating that PARP inhibitors (or genetic 
PARPl deficiency) tends to favor the male gender in models as diverse 
as endotoxin-induced organ inj ury [12] and ischemic stroke [44]. This 
may be related to a physiological inhibitory effect of estrogen on PARP 
activation (reviewed in [19] ). Because this effect of estrogen is expected 
to be reduced in aged (le. postmenopausal) female organisms, we have 
expected that in aged female mice, the benefit of olaparib would be re-
established. Indeed, this was the case (at least for some injury markers, 
such as ALP and ALT, which were suppressed by olaparib in aged fe-
male mice. However, other markers, e.g. amylase, or BUN remained 
unaffected by olaparib in this animal population) . Surprisingly, we have 
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Fig. 24. Effect of olaparib on PARP act ivation and cellular NAD+ levels in 
U937 cells subjected ta H20 2-induced oxidative stress in vitro. (A): Western 
blotting for PARPl (top lanes), polyADP-ribose (PAR), the enzymat ic praduct of 
PARP activation (middle lanes) and actin loading cont rai (bottom lanes) in 
U937 cells treated with olaparib (1, 3, 10, 30 or 100 µM ) in contrai and in 300 
µM H2 0 2 ("H") challenged cells at 1 h. Note the increase in PAR ( indicative of 
PARP activation) in response ta oxidat ive stress, and the full i nhibit ion of this 
response at ail olaparib concentrations tested. The expression of PARP l was 
unaffected by olaparib in any of the contrai conditions tested. However, in the 
oxidatively stressed cells, in the presence of olaparib, t he expression of PARPl 
also appeared ta be downregulated. Western blots shown are representative of 
experiments performed on 3 different experimental days. (B): Effect of olaparib 
on the cellular NAD + levels in contrai cells (without oxidative st ress challenge). 
Cells were treated with olaparib (1 , 3, 10, 30 or 100 µM) for 1 h. Data are show n 
as mean ± SEM ofn = 3 determinations. (C): Effect of olaparib on the cellular 
NAD+ levels in cells subjected to oxidative (H20,). Cells were treated with 
olaparib (1 , 3, 10, 30 or 100 µM), followed immediately by 300 µM H2 0 2 for 
1 h. Data are shown as mean ± SEM of n = 3 determinations. *p < 0.05 
shows significant decrease in NAD+ levels in response ta H20 2, compared ta 
contrai cells; # p < 0.05 shows significant pratective effect of olaparib in H20 2 
challenged cells compared to vehicle-treated H20 2 challenged cells. 
observed only a limited degree of beneficial effects of olaparib in aged 
male mice - with one isolated effect (protection against the increase in 
the pancreatic injury marker amylase). Overall, the effects of olapar ib 
in aged mice (male or female) tended to be less pronounced than the 
effects in young adult male mice. This find ing is consistent with several 
lines of studies indicating that in aged organisms, d ifferent sets of pa-
thophysiological mechanisms become mobilized than in young adult 
animais; among many differences, aged organisms appear to lose the 
ability to mobilize Nrf2, a master switch of antioxidant defense [30]. 
There are many additional possibilities as well. For instance, it is con-
ceivable that the regulation of PARPl expression and or activity may be 
age-dependent, and this should be a subject of further investigations. 
Indeed, lymphocytes from old subjects show a 50% red uction in the 
constitutive expression level of both parp 1 and parp 2 genes compared 
to young subjects [45]. The vast array of mechanisms responsible for 
multiple organ injury, immune and inflammatory responses and mor-
tality associated with sepsis remain to be further charac ter ized. 
Nevertheless, the findings reported in the current study clearly indicate 
that different populations (age and gender) may respond to the same 
insult with quantitatively d ifferent pathophysiological mechanisms, 
which, in turn, may require different (matching) experimental ther-
apeutic approaches (or a combina tion of these) . 
What, then, is the principal mechanism of olaparib in sepsis? As 
with most in vivo studies, it is difficult to decipher the exac t sequence of 
interrelated effects. We believe that the most likely answer is tha t 
olaparib exerts multiple effects a t various levels and a t multiple inter-
related checkpoints of sep tic shock (Fig. 31 ). One of these effects may 
be the preservation of cellular high-energy nucleotides, and inh ib ition 
of cell dysfunction (e.g. cellular bioenergetic impairments, or full-scale 
cell death such as cell necrosis) [19]. In addition - probably through 
interaction with a number of nuclear signaling mechanisms [33,46,47], 
olaparib down-regulates the production of multiple circulating 
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Fig. 25. Effect of olaparib on cellular viability in U937 cells subjected to H20 2 -induced oxidative stress in vitro. (A): Effect of olaparib on cellular resazurin reduction 
in control cells (without oxidative stress challenge) and in cells subjected to oxidative (H20z) in the presence of various concentrations of olaparib. Cells were treated 
with olaparib (1, 3, 10, 30 or 100 µM), followed immediately by 300 µM H20 2 for1 h. Data are shown as mean ± SEM ofn = 3 determinat ions. *p < 0.05 shows 
significant decrease in resazurin conversion in response to H2 0 2, compared to control cells; #p < 0.05 shows significant protective effect of olaparib in H20 2 
challenged cells compared to vehicle-treated H20 2 challenged cells. (B): Effect of olaparib on LDH content (a marker of cell necrosis) in the supernatant of contrai 
cells (without oxidative stress challenge) and in cells subjected to oxidative (H20 2) in the presence of various concentrations of olaparib. Cells were treated with 
olaparib (1, 3, 10, 30 or 1 OO µM), followed immediately by 300 µM H20 2 for 1 h. Data are shown as mean ± SEM of n = 3 determinations. 
mediators [1 9]. The current results also point to several additional 
mechanisms that have not been previously documented in the literature 
(with olaparib or with any of the earlier classes of PARP inhibitors). 
One of them may be the effect of olaparib on the composition of splenic 
and circulating immune cells, including Treg and Th17 lymphocytes. 
Another, likely closely related mechanism may be the effect of olaparib 
on bacterial clearance: in animals tteated with the highest dose of 
olaparib, there was a marked suppression in circulating and splenic 
CFUs, indicating that the PARP inhibitor may have, in some way, sti-
mulated bacterial elimination / antibacterial immune responses. This 
effect of olaparib does not appear to be a direct effect on the bacteria 
(since olaparib did not affect E. coli growth rates in vitro) and did not 
affect elimination of an R coli bolus in an in vivo model of bacteremia 
without septic shock and without mortality. It is conceivable that the 
effect of olaparib on T-cell populations may have contributed to a re-
adjustment of the immune responses in response to intestinal tissue 
damage and polymicrobial sepsis. 
What, then, is the mechanism (and functional consequence) of the 
changes in T-cell subpopulations reported in the current study? 
Regulatory T lymphocytes (Tregs) are immunosuppressive cells, and 
Tregs are elevated in patients with sepsis (48]. Previous studies have 
demonsttated that PARP-1 negatively regulates the regulatory T lym-
phocyte (Treg) (CD4 + CD25 + FoxP3 + ) by poly-ADP-ribosylating 
FoxP3. Its deletion makes the expression of FoxP3 more persistent and 
stable, conferring a more intense suppressive activity to the Treg lym-
phocytes. PARPl deficient mice have been shown to have a higher 
number ofTregs in peripheral lympha tic organs and in the thymus [ 49]. 
In the current study, olaparib, on its own (i.e. in mice not subjected to 
ClP), did not affect the Treg populations. It is not surprising that long-
term, complete deletion of PARPl has a different effect on cell ma-
turation and selection than a short-term, partial pharmacological in-
hibition of the same enzyme. However, when the animals were sub-
jected to ClP, olaparib partially counterac ted the increase in splenic 
Treg cell populations (Fig. 12). Tregs are known to redu ce amount and 
activity of immune effector cells, causing a state of immunosuppression 
that compromises the ability to eliminate bacteria (50]. Therefore, part 
of our working hypothesis is that the partial prevention of CLP-induced 
Tregs may prevent immunosuppression and may facilitate the elim-
ination of bacteria during CLP. 
Thl 7 cells are a proinflammatory lineage producing cytokines that 
increase inflammation, free radical production and organ damage. In 
the spleen, the number of Thl 7 cells was unaffec ted by CLP, but in the 
blood, the number of Thl 7 cells decreased, but, in line with prior 
findings (51] , the percentage of these cells increased. From all four 
groups of mice tested, the lowest number of Th17 populations were 
observed in the CLP + olaparib group. This may be interpreted as fol-
lows: that although - when considering the total number of cells - the 
animals subjected to CLP are suffering from lymphopenia, the pro-in-
flammatory lymphocyte profile is more intense. However, importantly, 
in the olaparib treated CLP mice, Th17 cell populations are reduced, 
rendering the Th17/Treg ratio lower and thereby reducing the in-
flamma tian. It is important to emphasize in this context tha t (a) the 
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treated cells at 1 h in the presence of pretreatment with 10 µM 
olaparib. Arrows indicate the addition of specific mitochon-
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Thl 7 !Treg ratio positively carrela tes with the SOFA scores and the 
higher the relation, the greater the adverse outcome in patients with 
sepsis [27) and (b) in our model, the spleen had a lower Th17;Treg 
ratio in QP-olaparib group when compared to CIP-vehicle. Indeed, the 
reduced Thl 7 !Treg ratio after olaparib treatment was also associated 
with a reduction in some inflammatory cytokines and also with an 
improved histopathological picture in the liver. Since Thl 7 cells are 
responsible for causing immunopathology during inflammation, the 
beneficial effects of olaparib on various indices or organ injury may be -
directly or indirectly - connected to the effect of olaparib on Thl 7 cell 
numbers. However, it is also conceivable that the protective effects of 
olaparib occur a t several different molecular and cellular targets - in-
cluding the production and/or action of reactive oxidants and free ra-
dicals, the development of vascular - e-g. endothelial - dysfunction, the 
-e- Contrai 
+ H20 2 
-......- Olap+H20 2 
-e- Contrai 
+ H20 2 
-......- Olap+H202 
regulation of pro-inflammatory cytokines, chemokines and other so-
luble mediators, and so on. Taken together, our working hy pothesis is 
that olaparib may help to maintain some degree of immune homeostasis 
after CLP by, on one hand, reducing inflammation and organ damage 
(through modulating Th17), while concomitantly preventing some 
immunosuppression caused by Treg activi ty (through modulating 
Tregs), thereby keeping the hast able to fight bacteria. 
PARP is known to act in conjunction with NF-11:B to regulate the 
activation and transcription of genes responsible for the inflammatory 
response: PARP knockout animals are known to have reduced produc-
tion of cytokines and other proinflammatory proteins that are under the 
control of the NF-11:B system [1 1). NF-11:B - b esides activating mRNA 
production - also activa tes the epigenetic regulation of the expression of 
several genes, through the production of microRNAs. Our study 
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Fig. 27. Effect of olaparib on oxidative phosphorylation-related bioenergetic parameters in U937 cells subjected to H20 2-induced oxidative stress in vitro. Results are 
shown in contrai cells, in H20 2 (300 µM) treated cells at 1 h, and in H20 2 (300 µM) treated cells at 1 h in the presence of pretreatment with 1, 3 or 10 µM olaparib. 
Results are indicated as mean ± SEM of n = 3 per condition. *p < 0.05 shows a significant change in response to H20 2, compared to contrai cells; #p < 0.05 and 
# # p < 0.01 show significant protective effect of olaparib in H20 2 challenged cells compared to vehicle-treated H20 2 challenged cells. 
suggests that the PARP inhibitor olaparib has an action of epigenetic 
regulation, since it modifies the production of several miRNA related to 
the differentiation and activation of Tregs and Thl 7 cells. Although 
miRNAs are known to regulate a host of cellular responses in health and 
disease [52-55], at this time, we don't know enough about the function 
of each of the microRNAs studied here to integrate the findings into a 
coherent mechanistic hypothesis. However, some information related to 
microRNAs is intriguing in the context of the current findings. For in-
stance, the 15a-5p miRNA is known to serve as a tumor suppressor and 
is reduced in plasma from sepsis patients who survived when compared 
to those who did not survive [56,57]. Moreover, overexpression of 17a-
5p miRNA reduces the suppressor activity of regulatory T lymphocytes 
[58-60]. In our study, olaparib treatment tended to normalize 
miRNAl 5 and miRNAl 7 levels in septic animals, and olaparib tteat-
ment was also accompanied by a partial normalization of Treg cell 
counts in a,p animals. Whether the number ofTreg cells was regulated 
through olaparib's action on miRNAl Sa and/ or miRl 7 levels remains to 
be further explored. 
The 365-Sp miRNA, expressed in patients with sepsis, is an im-
portant negative regulator of IL-6 [61 ,62]. Its expression was elevated 
in the spleen of CLP-vehicle group, and this was attenuated by olaparib. 
It is conceivable - but remains to be fur ther tested - that the attenuation 
of IL-6 levels by olaparib may occur (par tially or wholly) through its 
action on miRNA365. 
Although not a DNA repair enzyme perse, PARPl has been im-
plicated in the maintenance of DNA integrity, chiefly through the re-
cruitment of various DNA repair enzymes and the assembly of nuclear 
and mitochondrial DNA repair complexes [33, 36,63]. In fact, inhibition 
of DNA repair is the principal mode of action of olaparib's approved 
indication in the field of oncology [21]. However, a few th ings need to 
be kept in perspective in this regard (these considerations are discussed, 
in detail, in our recent position paper [19] and are only briefly re-
iterated here). First of all, the effect of olaparib on DNA repair is 
especially pronounced when cells harbor specific mutations (e.g. mu-
tations in the BRCA gene), and often in combination with treatment 
with cytotoxic and/or genotoxic chemotherapeu tic agents; in healthy 
cells, the effects of PARP inhibitors are less pronounced. Second, for the 
DNA repair effects of PARP inhibitors to be markedly efficient, a high 
degree of PARPl inhibition must be achieved: thus, the doses of the 
PARP inhibitor to be effective as an anticancer agent are substantially 
higher than the doses of the PARP inhibitor to be effective as a cyto-
protective or anti-inflammatory agent in non-oncological indications. 
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Fig. 28. Effect of olaparib on glycolysis-related bioenergetic parameters in U937 cells subjected to H2 0 2-induced oxidative stress in vitro. Results are shown in contrai 
cells, in H20 2 (300 µM) treated cells at 1 h, and in H20 2 (300 µM) treated cells at 1 h in the presence ofpretreatment with 1, 3or10 µM olaparib. Results are indicated 
as mean ± SEM of n = 3 per condition. *p < 0.05 shows a significant change in response to H2 0 2, compared to contrai cells; # p < 0.05 shows significant 
protective effect of olaparib in H2 0 2 challenged cells compared to vehicle-treated H20 2 challenged cells. 
This was also clear from the results of the current study, where olaparib 
a t 3- 10 mg/kg doses, exerted effects against multiple organ failure, 
inflammatory and immune dysregulation, and · at 10 mg/kg · also 
improved survival rates. These doses are at least one order of magni-
tude lower than the doses of ola parib tha t exert anticancer effects in 
vivo in tumor-bearing mice [1 9]. 
A distinction should also be made between the role of PARP in the 
regulation of nuclear and mitochondrial DNA integrity; we have re-
cently demonstrated that PARPl deficient cells may have some deficits 
or delays in nuclear DNA repair, but at the same time their mitochon-
drial DNA repair systems are, paradoxically, more efficient (36]. In line 
with these findings, we have, in fact, demonstrated tha t olaparib exerts 
beneficial effects against the loss of mitochondrial DNA integrity, bath 
in vivo and in vitro. Since the loss of mitochondrial DNA integrity can, 
subsequently, be associated with the active release of damaged mi-
tochondrial DNA from the cells, and this mitochondrial DNA can, in 
turn, induce inflammatory responses in adjacent cells (26] the current 
findings raise the possibility that inhibition of such a response by ola-
parib may be an additional model of its beneficial action. However, this 
possibility remains to be tested in future experiments. 
The methodology used in the current study to assess mitochondrial 
and nuclear DNA integrity (the 'LA-qPCR' assay) is technically h ighly 
reliable and it is widely used in the literature 64,65]. Although we d id 
not observe differences in nuclear DNA and mitochondrial DNA in-
tegrity using this assay, this does not necessar ily mean that inh ibition of 
PARP does not affect nuclear and mitochondrial DNA repair or DNA 
integrity in general. One of the limita tions of LA-qPCR is that it mea-
sures only DNA polymerase protruding DNA lesions such as DNA 
breaks. However, for example 8-oxoG, which is the most frequently 
occurring DNA damaged induced by the oxidative stress, will be by-
passed during PCR amplification and consequently will not affect the 
measured DNA integrity. Another limitation of the LA-qPCR is that it 
will not reflect DNA repair capacity (Le. the kinetics of the DNA repair 
process). In addition, since LA-qPCR measures changes in gene-specific 
integrity it is possible that other DNA regions, par ticular ly in the nu-
clear DNA, may be affected but not detected by the LA-qPCR. Moreover, 
the assay does not measure other types of DNA injury (e.& base mod-
ifications, or larger scale aberrations like micronucleus instability or 
chromosomal alterations) (64,65]. To assess the effect of olaparib on 
these parameters, further studies needed to be conducted. Nevertheless, 
it should be pointed out tha t ours is not the only report that demon-
strates that PARP inhibitors can exert beneficial effec ts in critical illness 
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Fig. 29. Effect of olaparib on bioenergetic parameters in U937 cells subjected to H20 2-induced oxidative stress in v itro: energy phenotype graphs. Representative 
energy phenotype graph showing contrai, H20 2 (300 µM) treated cells and H20 2 (300 µM) treated cells in the presence of 10 µM olaparib pretreatment. Open boxes 
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complete or near-complete restoration of these alterations. Results are indicated as mean ± SEM of n = 3 per condition. 
models without adverse effects. For instance, Hauser and colleagues 
have demonstrated that a PARP-1 inhibitor of another structural class 
than olaparib (IN0-1001) facilitates hemodynamic stabilization in a 
porcine aortic cross-clamp model, without adversely affecting DNA 
integrity (in that particular study, DNA integrity was assessed by the 
cornet assay, i.e. single-cell gel electrophoresis) [1 4]. 
Overall, in the context of the experimental therapy of sepsis, it ap-
pears tha t it is possible to find doses or concentrations of ola parib that 
exert beneficial effects in terms of organ function, immunological 
parameters, circulating media tors and survival (in vivo) or cell viability 
and cellular bioenergetics (in vitro), without adversely affecting DNA 
integrity. 
S. Conclusions 
Based on the studies in mice subjected to CIP, we conclude that 
olaparib can improve organ function and extend survival in septic 
shock. These effects are, at least in par t, due to an enhancement of 
antibacterial clearance, which may be related to the modulation of 
various splenic, thymie and blood T-lymphocyte subpopulations and/ or 
due to effects on multiple circulating chemokine or cytokine levels. 
According to our working hypothesis, on one hand, olaparib is ab le to 
reduce inflammation and organ damage (perhaps through reduction of 
Thl7 cell numbers in CLP) while, on the other hand, blocking im-
munosuppression caused by affec ting Tregs and thereby preserving hast 
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Fig. 30. Effect of olaparib on mitochondrial DNA integrity, mitochondrial DNA copy nnmber and nnclear DNA integrity in U937 cells snbjected to H20 2-indnced 
oxidative stress in vitro. (A): Mitochondrial DNA integrity, mitochondrial DNA copy nnmber and nnclear DNA integrity in control U937 cells (withont oxidative 
stress) snbjected to vehicle or varions concentrations of (1, 3, 10, 30 or 100 µM) olaparib for 24 h (data expressed as% of control); (B): Mitochondrial DNA integrity, 
mitochondrial DNA copy nnmber and nnclear DNA integrity in control U937 cells (withont oxidative stress) snbjected to vehicle or varions concentrations of olaparib 
(1, 3, 10, 30 or 100 µM), followed by treatmentwith H20 2 (300 µM) for 24 h (data expressed as% of control); (C): Mitochondrial DNA integrity, mitochondrial DNA 
copy nnmber and nnclear DNA integrity in control U937 cells (withont oxidative stress) snbjected to vehicle or varions concentrations of olaparib (1, 3, 10, 30 or 100 
µM), followed by treatment with H20 2 (1 mM) for 24 h (data expressed as% of control). Resnlts are indicated as mean ± SEM of n ~ 3 per condition. *p < 0.05 
shows a significant change in response to H20 2, compared to control cells; #p < 0.05 shows significant protective effect of olaparib in H20 2 challenged cells 
compared to vehicle-treated H20 2 challenged cells. 
antimicrobial functions. We have also confirmed prior data indicating 
that the effect of PARP inhibitors is preferentially manifesting in young 
adult male mice. However, in aged animais - i.e. old male mice and 
especially in old female mice - olaparib remained partially effective in 
protecting against multiorgan injury. Based on measurement of mi-
tochondrial and nuclear DNA integrity in vivo (tissues obtained from 
mice subjected to CLP) and in vitro (human monocytic cell lines 
subjected to oxidative stress), olaparib, in the dose range (1-10 mg/kg) 
and concentration range (1-100 µM) tested did not exert adverse effects 
on nuclear DNA integrity and exerted a protective effect against mi-
tochondrial DNA damage and mitochondrial function. Taken together, 
the current results suggest that olaparib exerts beneficial effects in 
sepsis and supports the concept of repurposing and clinical introduction 
of this PARP inhibitor for the experimental therapy of septic shock. 
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